- Home
- NBIS vs CRNX Comparison
NBIS vs CRNX Comparison
Compare NBIS & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIS
- CRNX
- Stock Information
- Founded
- NBIS N/A
- CRNX 2008
- Country
- NBIS
- CRNX United States
- Employees
- NBIS 26361
- CRNX N/A
- Industry
- NBIS
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- NBIS
- CRNX Health Care
- Exchange
- NBIS NYSE
- CRNX Nasdaq
- Market Cap
- NBIS 6.5B
- CRNX 5.2B
- IPO Year
- NBIS N/A
- CRNX 2018
- Fundamental
- Price
- NBIS $29.00
- CRNX $55.35
- Analyst Decision
- NBIS
- CRNX Strong Buy
- Analyst Count
- NBIS 0
- CRNX 10
- Target Price
- NBIS N/A
- CRNX $74.40
- AVG Volume (30 Days)
- NBIS N/A
- CRNX 594.1K
- Earning Date
- NBIS N/A
- CRNX 11-12-2024
- Dividend Yield
- NBIS N/A
- CRNX N/A
- EPS Growth
- NBIS N/A
- CRNX N/A
- EPS
- NBIS N/A
- CRNX N/A
- Revenue
- NBIS N/A
- CRNX $1,038,999.00
- Revenue This Year
- NBIS N/A
- CRNX N/A
- Revenue Next Year
- NBIS N/A
- CRNX $195.21
- P/E Ratio
- NBIS N/A
- CRNX N/A
- Revenue Growth
- NBIS N/A
- CRNX N/A
- 52 Week Low
- NBIS N/A
- CRNX $33.67
- 52 Week High
- NBIS N/A
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- NBIS N/A
- CRNX 45.55
- Support Level
- NBIS N/A
- CRNX $52.85
- Resistance Level
- NBIS N/A
- CRNX $56.15
- Average True Range (ATR)
- NBIS 0.00
- CRNX 2.36
- MACD
- NBIS 0.00
- CRNX -0.32
- Stochastic Oscillator
- NBIS 0.00
- CRNX 29.91
About NBIS NEBIUS GROUP N V
Nebius Group NV is a tech company. It is a European provider of infrastructure and services to AI builders globally. The group builds full-stack infrastructure to service the growth of the AI industry, including the scale of GPU clusters, cloud platforms, tools, and services for developers. It has R&D hubs across Europe, North America and Israel.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.